HUTCHMED (China) HMDCF
NASDAQ HMDCF
$2.16 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

HUTCHMED (China) (HMDCF) Other Accumulated Expenses (2015 - 2026)

HUTCHMED (China)'s (HMDCF) quarterly Other Accumulated Expenses came in at $4.5 million in Q2 2026, down 12.47% year-over-year from $5.1 million in Q2 2025, and down 9.77% quarter-over-quarter from $5.0 million in Q4 2025.

Analysis

HUTCHMED (China) (HMDCF) Other Accumulated Expenses (2015 - 2026) Analysis & Trends

HUTCHMED (China) (HMDCF) has reported Other Accumulated Expenses for 12 consecutive years, with $4.5 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Other Accumulated Expenses fell 12.47% year-over-year to $4.5 million in Q2 2026; TTM through Jun 2026 was $4.5 million, a 12.47% decrease from a year earlier, with the FY2025 full-year figure at $5.0 million, down 60.21% from the prior year.
  • Other Accumulated Expenses was $4.5 million for Q2 2026 at HUTCHMED (China), down from $5.0 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $37.2 million in Q2 2022 and troughed at $4.5 million in Q2 2026.
  • A 5-year average of $11.1 million and a median of $6.8 million in 2023 frame the typical range for Other Accumulated Expenses.
  • Across the five-year window, Other Accumulated Expenses jumped 443.17% in 2022 and plunged 81.71% in 2023, its largest moves.
  • Over 5 years, Other Accumulated Expenses stood at $12.2 million in 2022, then decreased by 14.2% to $10.5 million in 2023, then increased by 19.09% to $12.5 million in 2024, then plunged by 60.21% to $5.0 million in 2025, then fell by 9.77% to $4.5 million in 2026.
  • The last three Other Accumulated Expenses figures came in at $4.5 million (Q2 2026), $5.0 million (Q4 2025), and $5.1 million (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 210.97 Bn 196.98 Bn 7.24 Bn
2 Gilead Sciences 180.98 Bn 177.80 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.09 Bn 124.24 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.56 Bn 74.57 Bn 3.93 Bn
5 Argenx Se 61.71 Bn 56.53 Bn 1.37 Bn
6 Moderna 54.60 Bn 49.46 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.02 Bn 30.71 Bn 992.69 Mn
8 Biogen 31.25 Bn 29.97 Bn 1.96 Bn
9 Roivant Sciences 29.76 Bn 29.76 Bn 1.16 Mn
10 HUTCHMED (China) 376.85 Mn 391.04 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 4.48 Mn
Dec 31, 2025 4.96 Mn
Jun 30, 2025 5.12 Mn
Dec 31, 2024 12.48 Mn
Jun 30, 2024 6.05 Mn
Dec 31, 2023 10.48 Mn
Jun 30, 2023 6.81 Mn
Dec 31, 2022 12.21 Mn
Jun 30, 2022 37.25 Mn
Dec 31, 2021 17.19 Mn
Jun 30, 2021 6.86 Mn
Mar 31, 2021 5.58 Mn
Dec 31, 2020 4.38 Mn
Jun 30, 2020 3.93 Mn
Dec 31, 2019 5.86 Mn
Sep 30, 2019 4.07 Mn
Jun 30, 2019 5.36 Mn
Mar 31, 2019 3.21 Mn
Dec 31, 2018 26.61 Mn
Jun 30, 2018 31.16 Mn